Response to ASX Aware Letter
Filed with ASX · · 6 pages · English
Earlier from LTR Pharma
- LTR Secures Exclusive U.S. Pharmacy Partner for ROXUS
- LTR Secures First U.S. Commercial Agreement for ROXUS
- SPONTAN® Phase II interim data demonstrates rapid onset and pharmacokinetic profile addressing FDA Pre-IND requirements across adult and ≥65 populations
- SPONTAN Phase II data show rapid onset, support FDA pathway
- SPONTAN Phase II Clinical Study Completes Recruitment
Later from LTR Pharma
- LTR Executes Definitive U.S. Commercial Agreement with Shed
- LTR Executes U.S. Commercial Agreement with Strive
- SPONTAN Real-World Study Reports 93% Response
- FY26 Results Announcement
- SPONTAN Phase II Final Results
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma